• linkedin
  • Increase Font
  • Sharebar

    Real-world outcomes with aflibercept better in treatment-naïve patients

    Large study also finds better outcomes with consistent dosing regimen

    The global burden of neovascular age-related macular degeneration (AMD) is expected to increase as the population ages, and (to date) the anti-vascular endothelial growth factor (VEGF) drugs are considered first-line treatment, based on the results from numerous pivotal studies. Those studies led to the approval of both aflibercept and ranibizumab (and pegaptanib, although that compound is rarely used as a first-line treatment these days).

    Evidence remains strong that this class of drug is both efficacious and safe across a wide range of neovascular AMD patients.

    What about real-world outcomes?

    Clinicians do not yet know if treat-and-extend, PRN, or some other dosing regimen is best. Conflicting reports suggest that when anti-VEGF therapy is stopped, the clinical aspects of the disease return sooner than anticipated, making a case for continual monthly dosing.

    Investigating the effectiveness of aflibercept (Eylea, Regeneron) in patients with wet AMD, (PERSEUS) is a prospective, observational, non-controlled, multicenter cohort study to describe follow-up and treatment patterns in routine practice in 942 patients with AMD (treatment-naïve or previously treated) across 66 clinics in Germany. “Previously treated” in this study meant patients who received any pre-treatment.

    Study background


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';